Company Description
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease.
It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer.
In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).
Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications.
The company is based in New York, New York.
| Country | United States |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 37 |
| CEO | Sandesh Seth |
Contact Details
Address: 100 Park Avenue, 23rd Floor New York, New York 10017 United States | |
| Phone | 646 677 3870 |
| Website | actiniumpharma.com |
Stock Details
| Ticker Symbol | ATNM |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001388320 |
| CUSIP Number | 00507W107 |
| ISIN Number | US00507W2061 |
| Employer ID | 88-0378336 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sandesh C. Seth M.B.A., M.S. | Chairman and Chief Executive Officer |
| Steven O'Loughlin BS | Chief Financial Officer and Corporate Secretary |
| Dr. Paul Diamond Esq., Ph.D. | Vice President of Patent and Legal Counsel |
| Dr. Avinash Desai M.D. | Chief Medical Officer |
| Jenny Hsieh | Chief Strategy Officer |
| Caroline Yarbrough | Chief Commercial Officer |
| Lynn M. Bodarky M.B.A. | Chief Business Officer |
| J. C. Simeon | Executive Director of Quality Assurance |
| Dr. Madhuri Vusirikala M.D. | Vice President of Clinical Development BMT and Cellular Therapy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 31, 2025 | 10-K | Annual Report |
| Nov 27, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | ARS | Filing |
| Nov 5, 2024 | 8-K | Current Report |
| Nov 5, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 4, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |